JY
IMDX

Jeff Yass’s Insight Molecular Diagnostics IMDX Stock Holding History

Jeff Yass’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-56,093
Closed -$184K – 14203
2026
Q1 		$184K Sell
56,093
-16,358
-23% -$95K ﹤0.01% 11782
2025
Q4 		$543K Buy
+72,451
New +$409K ﹤0.01% 8582
2025
Q3 		– Sell
-11,795
Closed -$35.6K – 13462
2025
Q2 		$35.6K Sell
11,795
-33,011
-74% -$99.8K ﹤0.01% 12202
2025
Q1 		$137K Buy
+44,806
New +$121K ﹤0.01% 11297
2023
Q2 		– Sell
-1,739
Closed -$12.3K – 12818
2023
Q1 		$12.3K Sell
1,739
-1,541
-47% -$11.4K ﹤0.01% 12165
2022
Q4 		$21K Buy
+3,280
New +$36.2K ﹤0.01% 11749
2022
Q3 		– Sell
-7,290
Closed -$131K – 13852
2022
Q2 		$131K Buy
+7,290
New +$166K ﹤0.01% 11198
2022
Q1 		– Sell
-955
Closed -$30.5K – 13686
2021
Q4 		$41K Sell
955
-221
-19% -$12.7K ﹤0.01% 12650
2021
Q3 		$84K Buy
+1,176
New +$108K ﹤0.01% 12157
2021
Q2 		– Sell
-3,089
Closed -$302K – 13040
2021
Q1 		$321K Buy
3,089
+1,792
+138% +$170K ﹤0.01% 10463
2020
Q4 		$62K Sell
1,297
-1,797
-58% -$65.9K ﹤0.01% 10688
2020
Q3 		$86K Buy
+3,094
New +$88.7K ﹤0.01% 10000
2020
Q2 		– Sell
-896
Closed -$44K – 10672
2020
Q1 		$44K Sell
896
-270
-23% -$13.2K ﹤0.01% 9729
2019
Q4 		$52K Sell
1,166
-897
-43% -$32.4K ﹤0.01% 9332
2019
Q3 		$87K Sell
2,063
-578
-22% -$22.7K ﹤0.01% 9614
2019
Q2 		$132K Buy
2,641
+1,193
+82% +$99.2K ﹤0.01% 9467
2019
Q1 		$114K Buy
+1,448
New +$93.4K ﹤0.01% 8194
2018
Q1 		– Sell
-519
Closed -$48K – 9920
2017
Q4 		$48K Buy
+519
New +$58.5K ﹤0.01% 8917
2017
Q2 		– Sell
-625
Closed -$74K – 9620
2017
Q1 		$74K Buy
+625
New +$72.2K ﹤0.01% 8497

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's IMDX Position: Q2 2026 in Review

Jeff Yass sold out of Insight Molecular Diagnostics (IMDX) in Q2 2026, closing a stake of 56,093 shares — an estimated $184K sold.

Jeff Yass first reported a position in IMDX in Q1 2017 and held it in 19 quarters. The position peaked at $543K in Q4 2025. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Jeff Yass reported no remaining Insight Molecular Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 56,093 Insight Molecular Diagnostics shares in Q2 2026, an estimated $184K.
  • Jeff Yass first reported a position in Insight Molecular Diagnostics in Q1 2017 and held it in 19 quarters.
  • Jeff Yass's Insight Molecular Diagnostics position peaked at $543K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.